Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database
Harvoni® showed a lower reporting frequency of hepatobiliary disorders and fewer drug ineffectiveness reports, suggesting it may be preferred over Epclusa® and Vosevi® in patients with preexisting liver or biliary conditions.
Authors
- Annalisa Capuano (ORCID: https://orcid.org/0000-0002-8653-2408)
- Federica Fraenza
- Cristina Scavone (ORCID: https://orcid.org/0000-0002-9216-922X)
- Raffaella Di Napoli (ORCID: https://orcid.org/0009-0009-4497-3836)
- Mirko Cardillo
- Daniele Pirozzi
- John Scicluna
Institutions
- Université de Bordeaux (FR)
- University of Campania "Luigi Vanvitelli" (IT)
- Regione Campania (IT)
- Pharmac (NZ)
- Link Campus University (IT)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1080/14740338.2025.2495180
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00